Breaking News, Collaborations & Alliances

Ironwood Earns $15M Astellas Milestone

Enrolls first patient in Phase III linaclotide trial

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ironwood Pharmaceuticals, Inc. has earned a $15 million development milestone payment from partner Astellas Pharma triggered by Astellas’ enrollment of the first patient in a Phase III trial of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C) in Japan. Astellas expects to complete this trial in 2016.   The companies entered a licensing agreement in 2009 to develop and commercialize linaclotide in Japan for the treatment of IBS-C, chronic constipation and other gast...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters